{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"16.7"},{"groupId":"OG003","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"Rate of participants who did not have Minimal Residual Disease (MRD) as assessed by flow cytometry.","groups":[{"description":"40 mg Selinexor given orally 2 to 3 hours prior to high dose-melphalan IV infusion\n\nMelphalan: Melphalan 100 mg/m\\^2 IV over 30-45 minutes.\n\nDexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).\n\nAutologous Hematopoietic Cell Transplantation (HCT): Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.\n\nFosaprepitant: Fosaprepitant at 150 mg IV on days -3 and -2.","id":"OG000","title":"Phase 1 Level 1: Selinexor Plus HDM HCT"},{"description":"60 mg Selinexor given orally 2 to 3 hours prior to high dose-melphalan IV infusion\n\nMelphalan: Melphalan 100 mg/m\\^2 IV over 30-45 minutes.\n\nDexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).","id":"OG001","title":"Phase 1 Level 2: Selinexor Plus HDM HCT"},{"description":"80 mg Selinexor given orally 2 to 3 hours prior to high dose-melphalan IV infusion\n\nMelphalan: Melphalan 100 mg/m\\^2 IV over 30-45 minutes.\n\nDexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).","id":"OG002","title":"Phase 1 Level 3: Selinexor Plus HDM HCT"},{"description":"80 mg Selinexor given orally 2 to 3 hours prior to high dose-melphalan IV infusion\n\nMelphalan: Melphalan 100 mg/m\\^2 IV over 30-45 minutes.\n\nDexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).\n\nAutologous Hematopoietic Cell Transplantation (HCT): Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.\n\nFosaprepitant: Fosaprepitant at 150 mg IV on days -3 and -2.","id":"OG003","title":"Phase 2: Selinexor Plus HDM HCT"}],"paramType":"NUMBER","populationDescription":"Evaluable participants","reportingStatus":"POSTED","timeFrame":"3 months post HCT","title":"Rate of Minimal Residual Disease (MRD)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}